Previous Close | 6.37 |
Open | 6.32 |
Bid | 2.51 x 1200 |
Ask | 6.28 x 1100 |
Day's Range | 6.25 - 6.36 |
52 Week Range | 5.31 - 7.26 |
Volume | |
Avg. Volume | 752,869 |
Market Cap | 674.608M |
Beta (5Y Monthly) | 1.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.27 |
Earnings Date | May 01, 2024 |
Forward Dividend & Yield | 0.24 (3.77%) |
Ex-Dividend Date | Feb 14, 2024 |
1y Target Est | 7.50 |
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company") today announced that it will report financial results for the first quarter of 2024 on Wednesday, May 1, 2024, after the market closes.